January 4, 2023 -- Hookipa Pharma, the developer of a new class of immunotherapies using an arenavirus platform, on Wednesday announced that it has been granted a $5 million milestone payment under a collaboration agreement with Gilead Sciences.
Hookipa said it completed and delivered a regulatory support package for Gilead's Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using the developer's arenaviral platform.
The first participant in the Phase 1 clinical trial is expected to be dosed in 2023.
"Chronic hepatitis B infection remains an area of considerable unmet need, and we look forward to seeing the potential impact of our novel arenaviral platform as a component of care," Joern Aldag, CEO of Hookipa, said in a statement.
Preclinical data on the hepatitis B vaccine as a potential component for a curative regimen were recently presented at the American Association for the Study of Liver Diseases (AASLD).
Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate.
Hookipa noted that it is eligible to receive milestone payments based on the achievement of specified development, regulatory, and commercial milestones up to a total of more than $190 million, and it is also eligible to receive tiered royalties on net sales.
Copyright © 2023 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
